As shown in Figure 3, genetically predicted PNPLA3 inhibition resulted in an increased risk of gout (OR: 1.83, 95% CI: 1.49 to 2.26, p=1.44 × 10−8) and idiopathic gout (OR: 2.42, 95% CI: 1.60 to 3.65, p=2.81 × 10−5) (Figure s3), but not for gout due to impaired renal function (OR: 1.25, 95% CI: 0.37 to 4.22, p=7.23 × 10−1). The gene discussed is PNPLA3; the disease is gout.